Preclinical development of a bispecific TNFα/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease

by Kevin J. Roberts, Marion F. Cubitt, Timothy M. Carlton, Lurdes Rodrigues-Duarte, Luana Maggiore, Ray Chai, Simon Clare, Katherine Harcourt, Thomas T. MacDonald, Keith P. Ray, Anna Vossenkämper, Michael R. West, J. Scott Crowe
Published 2021-09-01